ICD therapy: What have we learned from the clinical trials?

Arya, A. and Haghjoo, M. and Sadr-Ameli, M.A. (2006) ICD therapy: What have we learned from the clinical trials? Heart Lung and Circulation, 15 (1). pp. 3-11.

Full text not available from this repository.

Abstract

Development of implantable cardioverter defibrillators (ICD) has been a dramatic advancement in the management of patients with life-threatening ventricular arrhythmias. We hereby reviewed the landmark clinical trials on ICD with special emphasis on late-breaking clinical trials and assessed their impact on every-day decision making and patient selection for ICD implantation. © 2005 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier Inc. All rights reserved.

Item Type:	Article
Additional Information:	cited By 0
Uncontrolled Keywords:	amiodarone; antiarrhythmic agent; antilipemic agent; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase inhibitor; metoproterenol; placebo; proafenone; procainamide; sotalol; unclassified drug, bradycardia; cardiac resynchronization therapy; cardiovascular risk; clinical assessment; clinical study; clinical trial; congestive cardiomyopathy; congestive heart failure; coronary artery bypass graft; coronary artery disease; cost benefit analysis; cost utility analysis; defibrillator; follow up; health care cost; heart left ventricle ejection fraction; heart ventricle arrhythmia; heart ventricle tachycardia; high risk patient; human; learning; medical decision making; meta analysis; mortality; patient care; patient selection; priority journal; quality of life; review; risk benefit analysis; risk reduction; survival rate; systematic review; threat; treatment indication; unspecified side effect
Subjects:	WG Cardiovascular System
Depositing User:	Librarian Farzaneh Dini
Date Deposited:	08 Apr 2020 07:06
Last Modified:	08 Apr 2020 07:06
URI:	http://eprints.iums.ac.ir/id/eprint/12050

Actions (login required)

View Item